To fight the menace of cancer, there have been categorical and highly efficacious progress in the world of CAR-T therapy. Several companies have been contributing…

A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the appointment of two world-class experts – Dr. Marco Davila and…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary OmniCAR platform after unveiling two high-profile additions to its scientific…

Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and investors are taking notice, says Prescient Therapeutics chair Steven Engle….

One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its way through the year 2021 with great progression in clinical…

Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year 2022. The ASX-listed clinical stage oncology company continues to stand…

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8 million in…

Summary Prescient Therapeutics (ASX:PTX): We spoke with Steve Yatomi-Clarke, CEO of Prescient Therapeutics, about the exciting new world of CAR-T therapy for the treatment of cancer and…

Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021. Steven introduced Prescient Therapeutics to a new range of investors,…

Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies as the company builds towards clinical testing. These studies –…